2022, Number 11
Primary non-Hodgkin´s lymphoma of vagina or cervix. A diagnosis sometimes uncertain: about a case
Full text
Language: Spanish
References: 20
Page: 916-923
PDF size: 340.11 Kb.
ABSTRACT
Background: Primary involvement of the female genital tract by non-Hodgkin's lymphoma is exceptional, reported in 0.2 to 1.1% of cases. The most frequently affected organs are the ovaries, followed by the cervix; the endometrium and vagina are the least affected. Due to their low frequency, there is still no consensus on the most appropriate treatment of these lymphomas; until now, it has generally been individualized for each specific case.Clinical case: A 29-year-old female patient consulted for abnormal genital bleeding and inability to insert vaginal tampons. On examination a pelvic mass was found, palpable through the vagina, which impressed by infiltrating the entire vaginal lumen and the middle and left side of the vulva. Imaging studies showed a large pelvic mass of up to 10 centimeters that appeared to be dependent on the cervix and that extended and infiltrated the vaginal canal, the vulva and the lower third of the bladder. The anatomopathological report of the biopsy was: infiltration of the vaginal wall by diffuse large cell non-Hodgkin's B lymphoma. She was prescribed six cycles of chemotherapy with cyclophosphamide, vincristine, adriamycin and prednisone with which complete metabolic remission was achieved.
Conclusion: The diagnosis of primary genital lymphoma can be complex because of the possibility of simulating a gynecologic neoplasm. In cases of advanced disease, the most frequent clinical manifestation is abnormal genital bleeding. The most accepted treatment scheme at present is rituximab-cyclophosphamide, vincristine, adriamycin, prednisone followed by consolidation radiotherapy.
REFERENCES
González-Díaz E, Argüelles S, De Cabo E, Salas S, et al.Afección vaginal de linfoma no hodgkiniano de célulagrandes difuso. Clin Invest Ginecol Obstet 2006; 33 (2):70-2. https://www.elsevier.es/es-revista-clinica-e-investigacion-ginecologia-obstetricia-7-articulo-afeccion-vaginallinfoma-no-hodgkiniano-13085722
Fu K, Weisenburger DD, Choi WWL, Perry KD, et al. Additionof rituximab to standard chemotherapy improvesthe survival of both the germinal center B-cell-like andnon-germinal center B-cell-like subtypes of diffuse largeB-cell lymphoma. J Clin Oncol 2008; 26 (28): 4587-94.https://experts.nebraska.edu/en/publications/addition-ofrituximab-to-standard-chemotherapy-improves-the-survi
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, etal. Long-term outcome of patients in the LNH-98.5 trial,the first randomized study comparing rituximab-CHOPto standard CHOP chemotherapy in DLBCL patients: Astudy by the Groupe d’Etudes des Lymphomes de l’Adulte.Blood 2010; 116 (12): 2040-45. https://doi.org/10.1182/blood-2010-03-276246
Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, et al.CHOP-like chemotherapy with or without rituximab inyoung patients with good-prognosis diffuse large-B-celllymphoma: 6-year results of an open-label randomisedstudy of the MabThera International Trial (MInT) Group.Lancet Oncol 2011; 12 (11): 1013-22. http://www.thelancet.com/article/S1470204511702352/fulltext